thalidomide has been researched along with Cough in 14 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Cough: A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the efficacy of thalidomide in suppressing cough in patients with IPF." | 9.16 | Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. ( Danoff, SK; Horton, KM; Horton, MR; Lechtzin, N; Liu, MC; Mathew, L; Polito, AJ; Santopietro, V, 2012) |
| "This report-the second of a series on codeine and its alternates for pain and cough relief-contains a detailed evaluation of experimental and clinical data on newer substances having analgesic properties comparable to and in approximately the same range as those of codeine." | 8.74 | Codeine and its alternates for pain and cough relief. 2. Alternates for pain relief. ( Eddy, NB; Friebel, H; Hahn, KJ; Halbach, H, 1969) |
| "The CQLQ was administered as an outcome within a previously published 27-week, placebo-controlled, crossover trial of thalidomide for cough in IPF." | 5.17 | Validation of the Cough Quality-of-Life Questionnaire in patients with idiopathic pulmonary fibrosis. ( Hilliard, ME; Horton, MR; Lechtzin, N, 2013) |
| "To determine the efficacy of thalidomide in suppressing cough in patients with IPF." | 5.16 | Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. ( Danoff, SK; Horton, KM; Horton, MR; Lechtzin, N; Liu, MC; Mathew, L; Polito, AJ; Santopietro, V, 2012) |
| " There was weak evidence for the improvement of 6MWD using oxygen; dyspnoea using prednisolone, diamorphine, D-pencillamine and colchicine; cough using interferon α and thalidomide; anxiety using diamorphine; fatigue using pulmonary rehabilitation; and QoL using thalidomide and doxycycline." | 4.89 | Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature. ( Bajwah, S; Higginson, IJ; Koffman, J; Patel, AS; Peacock, JL; Riley, J; Ross, JR; Wells, AU, 2013) |
| "This report-the second of a series on codeine and its alternates for pain and cough relief-contains a detailed evaluation of experimental and clinical data on newer substances having analgesic properties comparable to and in approximately the same range as those of codeine." | 4.74 | Codeine and its alternates for pain and cough relief. 2. Alternates for pain relief. ( Eddy, NB; Friebel, H; Hahn, KJ; Halbach, H, 1969) |
| "Lenalidomide is a derivative of thalidomide and is FDA-approved for the treatment of myelodysplastic syndrome and, in combination with dexamethasone, for the treatment of relapsed multiple myeloma." | 3.78 | Reversible pulmonary toxicity due to lenalidomide. ( Barker, A; Coates, S; Spurgeon, S, 2012) |
| "Few clinical trials have focused on treatments for IPF cough." | 2.55 | Etiology and treatment of cough in idiopathic pulmonary fibrosis. ( Horton, MR; Hughes, AH; Vigeland, CL, 2017) |
| " We conclude that severe lung toxicity should be included among the potential adverse effects of thalidomide." | 1.31 | [Lung toxicity due to thalidomide]. ( Bertomeu González, V; Carrión Valero, F, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y | 1 |
| Ren, XY | 1 |
| Sun, F | 1 |
| Wang, P | 1 |
| Zhao, JL | 1 |
| Wu, QJ | 1 |
| Zeng, XF | 1 |
| Lechtzin, N | 4 |
| Hilliard, ME | 1 |
| Horton, MR | 5 |
| Swigris, JJ | 1 |
| Brown, KK | 1 |
| Belkin, A | 1 |
| Vigeland, CL | 1 |
| Hughes, AH | 1 |
| Danoff, SK | 2 |
| Coates, S | 1 |
| Barker, A | 1 |
| Spurgeon, S | 1 |
| Santopietro, V | 1 |
| Mathew, L | 1 |
| Horton, KM | 1 |
| Polito, AJ | 1 |
| Liu, MC | 1 |
| Bajwah, S | 1 |
| Ross, JR | 1 |
| Peacock, JL | 1 |
| Higginson, IJ | 1 |
| Wells, AU | 1 |
| Patel, AS | 1 |
| Koffman, J | 1 |
| Riley, J | 1 |
| Carrión Valero, F | 1 |
| Bertomeu González, V | 1 |
| Díaz García, B | 1 |
| de Pablo Gafas, A | 1 |
| Ferreiro Alvarez, MJ | 1 |
| DiNino, KC | 1 |
| Eddy, NB | 1 |
| Friebel, H | 1 |
| Hahn, KJ | 1 |
| Halbach, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of Pomalidomide in the Treatment of Refractory Cough in Patients With Idiopathic Pulmonary Fibrosis (IPF): A Pilot Study[NCT01135199] | Phase 2 | 0 participants (Actual) | Interventional | 2010-04-30 | Withdrawn (stopped due to FDA did not accept sponsor's animal toxicology data to support proposed dosing.) | ||
| Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide[NCT00600028] | Phase 3 | 25 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary endpoint, suppression of cough was measured by the Cough Quality of Life Questionnaire (CQLQ) to measure the effect of interventions on cough-specific quality of life.~CQLQ consist of 28 questions about cough and its effects using Likert-like 4-point scales, with lower scores indicating less effect of cough on health related quality of life.~CQLQ scale ranges from 28 to 112 ( The lower the value, the higher the quality of life, 28 is considered the best)." (NCT00600028)
Timeframe: 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Arm Thalidomide 1st, Placebo 2nd (Intervention Thalidomide) | 47.3 |
| Arm Thalidomide 1st, Placebo 2nd (Intervention Placebo) | 55.2 |
| Arm Placebo 1st, Thalidomide 2nd (Intervention Placebo) | 61.6 |
| Arm Placebo 1st, Thalidomide 2nd (Intervention Thalidomide) | 44.5 |
"The secondary endpoint, suppression of cough was measured by the visual analog scale of cough (VAS) was significantly lower during treatment with thalidomide than placebo.~Secondary endpoints were Cough VAS - the visual analog scale of cough evaluates the severity of cough in patients with IPF.~Visual analog scale of cough ranges from 0 to 100 (0 is considered the best).~St. George Respiratory Questionnaire helps to evaluate cough-specific and respiratory quality of life in patients with IPF.~St. George Respiratory Questionnaire score ranges from 0 to 100 (0 is considered the best)." (NCT00600028)
Timeframe: 6 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Severity of cough (VAS Score) | Quality of life (SGRQ Score) | |
| Arm Placebo 1st, Thalidomide 2nd (Intervention Placebo) | 68 | 58.8 |
| Arm Placebo 1st, Thalidomide 2nd (Intervention Thalidomide) | 17.8 | 40.7 |
| Arm Thalidomide 1st, Placebo 2nd (Intervention Placebo) | 65.9 | 54.7 |
| Arm Thalidomide 1st, Placebo 2nd (Intervention Thalidomide) | 30.3 | 46.4 |
3 reviews available for thalidomide and Cough
| Article | Year |
|---|---|
Etiology and treatment of cough in idiopathic pulmonary fibrosis.
Topics: Antitussive Agents; Comorbidity; Cough; Gastroesophageal Reflux; Humans; Idiopathic Pulmonary Fibros | 2017 |
Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Cough; Dyspnea; Exercise | 2013 |
Codeine and its alternates for pain and cough relief. 2. Alternates for pain relief.
Topics: Amides; Analgesics; Animals; Antitussive Agents; Azepines; Carisoprodol; Cats; Chickens; Codeine; Co | 1969 |
3 trials available for thalidomide and Cough
| Article | Year |
|---|---|
Validation of the Cough Quality-of-Life Questionnaire in patients with idiopathic pulmonary fibrosis.
Topics: Aged; Chronic Disease; Cough; Cross-Over Studies; Disease Progression; Double-Blind Method; Female; | 2013 |
Thalidomide inhibits the intractable cough of idiopathic pulmonary fibrosis.
Topics: Antitussive Agents; Cough; Humans; Prospective Studies; Pulmonary Fibrosis; Thalidomide | 2008 |
Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial.
Topics: Aged; Antitussive Agents; Constipation; Cough; Dizziness; Double-Blind Method; Female; Humans; Idiop | 2012 |
8 other studies available for thalidomide and Cough
| Article | Year |
|---|---|
[The 456th case: polyarthritis, dry cough, dyspnea on exertion].
Topics: Arthralgia; Arthritis, Rheumatoid; Autoantibodies; Blood Sedimentation; C-Reactive Protein; Cough; D | 2017 |
Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis.
Topics: Antitussive Agents; Cough; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Thalidomide | 2013 |
Author reply: To PMID 22986377.
Topics: Antitussive Agents; Cough; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Thalidomide | 2013 |
Reversible pulmonary toxicity due to lenalidomide.
Topics: Antineoplastic Agents; Cough; Dyspnea; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Th | 2012 |
Summaries for patients. Thalidomide treatment for cough in patients with idiopathic pulmonary fibrosis.
Topics: Aged; Antitussive Agents; Constipation; Cough; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; | 2012 |
[Lung toxicity due to thalidomide].
Topics: Aged; Cough; Dyspnea; Follow-Up Studies; Humans; Immunosuppressive Agents; Lung; Male; Multiple Myel | 2002 |
[Lung toxicity due to thalidomide].
Topics: Cough; Dyspnea; Humans; Immunosuppressive Agents; Lung; Lung Diseases; Multiple Myeloma; Radiography | 2003 |
Rib pain and increased cough.
Topics: Biopsy; Cough; Diagnosis, Differential; Humans; Male; Middle Aged; Multiple Myeloma; Nurse Practitio | 2005 |